{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:07:30Z","timestamp":1793848050169,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.urology.2020.10.039","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T02:03:30Z","timestamp":1604973810000},"page":"11-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them"],"prefix":"10.1016","volume":"149","author":[{"given":"George E.","family":"Koch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woodson W.","family":"Smelser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.10.039_bib0001","article-title":"Cancer statistics, 2020","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2020.10.039_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.6_suppl.313","article-title":"A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder","author":"DeCastro","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.10.039_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2020.10.039_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0006","unstructured":"Swanson SK, Sellinger SB, Maddox-Smith A, Harris RG, Cookson MS, Nagler HM. 2020 Update regarding BCG shortage."},{"key":"10.1016\/j.urology.2020.10.039_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ucl.2013.01.005","article-title":"Side effects of perioperative intravesical treatment and treatment strategies for these side effects","author":"Griffin","year":"2013","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2020.10.039_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2007.08.015","article-title":"Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results","author":"Witjes","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0009","article-title":"Managing the adverse events of intravesical bacillus Calmette\u2013Guerin therapy","author":"Decaestecker","year":"2015","journal-title":"Res Reports Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0010","article-title":"Maintenance bacillus calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose an","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0012","article-title":"Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","author":"Lamm","year":"1995","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urology.2020.10.039_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette- Guerin therapy in superficial bladder cancer? interim results of European organization for research and treatment of cancer protocol 30911","author":"Vegt","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(01)66040-3","article-title":"The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma","author":"B\u00f6hle","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2012.10.070","article-title":"Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical bacillus Calmette-Gu\u00e9rin treatment","author":"Johnson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2006.03.066","article-title":"Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients","author":"Yossepowitch","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0019","first-page":"1","article-title":"(For intravesical use) TICE BCG","year":"2009","journal-title":"Packag Inser"},{"key":"10.1016\/j.urology.2020.10.039_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006885.pub2","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urology.2020.10.039_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00260","article-title":"Intravesical gemcitabine versus intravesical bacillus Calmette-Gu\u00e9rin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity","author":"Prasanna","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.urology.2020.10.039_bib0022","doi-asserted-by":"crossref","DOI":"10.1086\/344908","article-title":"Spectrum of bacille Calmette-Gu\u00e9rin (BCG) infection after intravesical BCG immunotherapy","author":"Gonzalez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.urology.2020.10.039_bib0023","doi-asserted-by":"crossref","DOI":"10.4137\/CCRep.S39904","article-title":"Disseminated mycobacterium Bovis infection complicating intravesical BCG instillation for the treatment of superficial transitional cell carcinoma of the bladder","author":"Elzein","year":"2016","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.urology.2020.10.039_bib0024","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical bcg administration as adjunctive therapy for bladder cancer incidence, risk factors, and outcome in a single-institution series and review of the literature","author":"As\u00edn","year":"2014","journal-title":"Med (United States)"},{"key":"10.1016\/j.urology.2020.10.039_bib0025","first-page":"1","article-title":"Gemzar (Gemcitabine for injection) U.S","year":"2014","journal-title":"Package Insert Prescribing Inform"},{"key":"10.1016\/j.urology.2020.10.039_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2009.05.094","article-title":"Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer","author":"Maffezzini","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.10.039_bib0027","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.10.039_bib0028","article-title":"Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","author":"Sternberg","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0029","article-title":"Mitomycin FDA label","year":"2015","journal-title":"Packag Inser"},{"key":"10.1016\/j.urology.2020.10.039_bib0030","doi-asserted-by":"crossref","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0031","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette- Guerin","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0033","doi-asserted-by":"crossref","DOI":"10.1046\/j.1464-410x.1999.00951.x","article-title":"Perivesical fat necrosis after adjuvant intravesical chemotherapy","author":"Doherty","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.10.039_bib0034","article-title":"A management algorithm for mitomycin C induced cystitis","author":"Luckenbaugh","year":"2017","journal-title":"Bl Cancer"},{"key":"10.1016\/j.urology.2020.10.039_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(05)67168-6","article-title":"Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin C","author":"Neulander","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0036","doi-asserted-by":"crossref","DOI":"10.1111\/j.1346-8138.2009.00668.x","article-title":"Drug eruption due to intravesical instillations of both epirubicin and mitomycin C","author":"Okumura","year":"2009","journal-title":"J Dermatol"},{"key":"10.1016\/j.urology.2020.10.039_bib0037","article-title":"Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection","author":"Filson","year":"2014","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urology.2020.10.039_bib0038","doi-asserted-by":"crossref","DOI":"10.1159\/000030242","article-title":"Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer","author":"Tsushima","year":"1998","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2020.10.039_bib0039","doi-asserted-by":"crossref","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus calmette-guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group phase III trial (30906)","author":"De Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0040","doi-asserted-by":"crossref","DOI":"10.1097\/00005392-199707000-00018","article-title":"Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study","author":"Ali-El-Dein","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0041","doi-asserted-by":"crossref","DOI":"10.1177\/1756287214541798","article-title":"Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder","author":"Cookson","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0042","series-title":"Complications of Urologic Surgery: Prevention and Management","author":"Taneja","year":"2017"},{"key":"10.1016\/j.urology.2020.10.039_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(19)30564-0","article-title":"A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC)","author":"Purshouse","year":"2019","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urology.2020.10.039_bib0044","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","author":"Steinberg","year":"2015","journal-title":"Bl Cancer"},{"key":"10.1016\/j.urology.2020.10.039_bib0045","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","author":"Milbar","year":"2017","journal-title":"Bl Cancer"},{"key":"10.1016\/j.urology.2020.10.039_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Gu\u00e9rin treatment failure","author":"McKiernan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.10.039_bib0047","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2008.07898.x","article-title":"Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C","author":"Stoehr","year":"2008","journal-title":"BJU Int"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520313492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520313492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:14:15Z","timestamp":1758766455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520313492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":47,"alternative-id":["S0090429520313492"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.10.039","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}